Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias D'huyvetter

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
Pharmaceutics|August 4, 2019
Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and MetastasesJanik Puttemans, Tony Lahoutte, Matthias D'Huyvetter, et al.
Molecular Pharmaceutics|March 6, 2018
Evaluation of an Anti-HER2 Nanobody Labeled with <sup>225</sup>Ac for Targeted α-Particle Therapy of CancerMarek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 13, 2022
A Realistic Multiregion Mouse Kidney Dosimetry Model to Support the Preclinical Evaluation of Potential Nephrotoxicity of Radiopharmaceutical TherapyClarita Saldarriaga Vargas, Lara Struelens, Matthias D'Huyvetter, et al.
EJNMMI Physics|February 23, 2022
Assessment of mouse-specific pharmacokinetics in kidneys based on <sup>131</sup>I activity measurements using micro-SPECTClarita Saldarriaga Vargas, Lara Struelens, Matthias D'Huyvetter, et al.
Expert Opinion on Drug Delivery|July 19, 2014
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancerMatthias D'Huyvetter, Catarina Xavier, Vicky Caveliers, et al.
Nuclear Medicine and Biology|April 13, 2016
(18)F-nanobody for PET imaging of HER2 overexpressing tumorsCatarina Xavier, Anneleen Blykers, Ilse Vaneycken, et al.
Expert Opinion on Biological Therapy|May 5, 2016
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicleYana Dekempeneer, Marleen Keyaerts, Ahmet Krasniqi, et al.
New Biotechnology|March 26, 2018
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20Ahmet Krasniqi, Magdalena Bialkowska, Catarina Xavier, et al.
Journal of Translational Medicine|November 5, 2024
CD38 as theranostic target in oncologyValentina Bocuzzi, Jessica Bridoux, Michelle Pirotte, et al.
Current Opinion in Biotechnology|July 6, 2011
Immuno-imaging using nanobodiesIlse Vaneycken, Matthias D'huyvetter, Sophie Hernot, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
Pharmaceutics|August 4, 2019
Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and MetastasesJanik Puttemans, Tony Lahoutte, Matthias D'Huyvetter, et al.
Molecular Pharmaceutics|March 6, 2018
Evaluation of an Anti-HER2 Nanobody Labeled with <sup>225</sup>Ac for Targeted α-Particle Therapy of CancerMarek Pruszynski, Matthias D'Huyvetter, Frank Bruchertseifer, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 13, 2022
A Realistic Multiregion Mouse Kidney Dosimetry Model to Support the Preclinical Evaluation of Potential Nephrotoxicity of Radiopharmaceutical TherapyClarita Saldarriaga Vargas, Lara Struelens, Matthias D'Huyvetter, et al.
EJNMMI Physics|February 23, 2022
Assessment of mouse-specific pharmacokinetics in kidneys based on <sup>131</sup>I activity measurements using micro-SPECTClarita Saldarriaga Vargas, Lara Struelens, Matthias D'Huyvetter, et al.
Expert Opinion on Drug Delivery|July 19, 2014
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancerMatthias D'Huyvetter, Catarina Xavier, Vicky Caveliers, et al.
Nuclear Medicine and Biology|April 13, 2016
(18)F-nanobody for PET imaging of HER2 overexpressing tumorsCatarina Xavier, Anneleen Blykers, Ilse Vaneycken, et al.
Expert Opinion on Biological Therapy|May 5, 2016
Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicleYana Dekempeneer, Marleen Keyaerts, Ahmet Krasniqi, et al.
New Biotechnology|March 26, 2018
Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20Ahmet Krasniqi, Magdalena Bialkowska, Catarina Xavier, et al.
Journal of Translational Medicine|November 5, 2024
CD38 as theranostic target in oncologyValentina Bocuzzi, Jessica Bridoux, Michelle Pirotte, et al.
Current Opinion in Biotechnology|July 6, 2011
Immuno-imaging using nanobodiesIlse Vaneycken, Matthias D'huyvetter, Sophie Hernot, et al.
Pageof 5